Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK: Will Companies Remaining In Voluntary Payment Scheme End Up With A Bigger Bill?

Executive Summary

Uncertainty over the payments that will be due from companies to manage the branded medicines bill in 2023 and beyond has been a cause for concern for firms, which last month had to decide whether to remain in or exit the Voluntary Scheme for Branded Medicines Pricing and Access. If many companies have left, the “remainers” might end up paying more than their fair share, though the government has offered some assurance on this front.

You may also be interested in...

More Execs Speak Out Over Risks Of UK Voluntary Pricing Scheme For Life Sciences

In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.

Two Big Pharma Firms Quit UK Pricing Scheme In Protest Over High Levies

Lilly says the current voluntary drug pricing and access scheme has harmed innovation and left the UK a “global outlier” among major countries, while AbbVie asserts that this year’s repayment rate of 26.5% will impair its ability to operate sustainably in the country. The industry body, the ABPI, says it will come up with proposals for a “completely new settlement” in the coming months.

UK Planning To Raise Industry Repayments Under Statutory Pricing Scheme

The UK government says that payments need to rise if the stability of the statutory and voluntary drug pricing schemes is to be ensured.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts